Hepatitis B in sub-Saharan Africa: strategies to achieve the 2030 elimination targets

The Lancet Gastroenterology and Hepatology

Volumn 2, Issue 12, 2017, Pages 900-

  Spearman, C Wendy ^a,b   Afihene, Mary ^c   Ally, Reidwaan ^d   Apica, Betty ^e   Awuku, Yaw ^f   Cunha, Lina ^g   Dusheiko, Geoffrey ^h   Gogela, Neliswa ^a,b   Kassianides, Chris ⁱ   Kew, Michael ^a,b   Lam, Philip ^j   Lesi, Olufunmilayo ^k   Lohouès Kouacou, Marie Jeanne ^l   Mbaye, Papa Saliou ^m   Musabeyezu, Emmanuel ⁿ   Musau, Betty ^o   Ojo, Olusegun ^p   Rwegasha, John ^q   Scholz, Barbara ^r   Shewaye, Abate B ^s   Tzeuton, Christian ^t   Sonderup, Mark W ^a,b   more..

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Ghana)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

^f UNIVERSITY OF CAPE COAST   (Ghana)

^g EDUARDO MONDLANE UNIVERSITY   (Mozambique)

^h ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

ⁱ Morningside Clinic   (South Africa)

^j Victoria Hospital   (Mauritius)

^k UNIVERSITY OF LAGOS   (Nigeria)

^l Université Félix Houphouet Boigny de Cocody   (Senegal)

^m Principal Hospital   (Senegal)

ⁿ King Faisal Hospital and Great Lakes Polyclinic   (Rwanda)

^o Nairobi Hospital   (Kenya)

^p OBAFEMI AWOLOWO UNIVERSITY TEACHING HOSPITALS COMPLEX   (Nigeria)

^q MUHIMBILI NATIONAL HOSPITAL   (Tanzania)

^r Roman Catholic Hospital   (Namibia)

^s ADDIS ABABA UNIVERSITY   (Ethiopia)

^t DOUALA GENERAL HOSPITAL   (Cameroon)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; ANTIVIRUS AGENT;

AFRICA SOUTH OF THE SAHARA; ANTIVIRAL THERAPY; CHILD HEALTH; HEALTH CARE PERSONNEL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFECTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; META ANALYSIS (TOPIC); MIXED INFECTION; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEROPREVALENCE; SYSTEMATIC REVIEW (TOPIC); VIRUS LOAD; BLOOD; HEALTH CARE DELIVERY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MASS IMMUNIZATION; MASS SCREENING; PREVALENCE; TRANSMISSION; VERTICAL TRANSMISSION;

AFRICA SOUTH OF THE SAHARA; ANTIVIRAL AGENTS; COINFECTION; HEALTH SERVICES ACCESSIBILITY; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HIV INFECTIONS; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MASS SCREENING; MASS VACCINATION; PREVALENCE;

EID: 85033464902     PISSN: 24681253     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2468-1253(17)30295-9     Document Type: Review

References (86)

1. GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390 (2017), 1151–1210.
2. WHO. Global hepatitis report, 2017. April, 2017, World Health Organization, Geneva www.who.int/hepatitis/publications/global-hepatitis-report2017/en/ (accessed July 24, 2017).
3. Stanaway, JD, Flaxman, AD, Naghavi, M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet 388 (2016), 1081–1088.
4. WHO. Global health sector strategy on viral hepatitis 2016–2021: towards ending viral hepatitis. 2016, World Health Organization, Geneva apps.who.int/iris/bitstream/10665/246177/1/WHO-HIV-2016.06-eng.pdf (accessed Feb 25, 2017).
5. Zampino, R, Boemio, A, Sagnelli, C, et al. Hepatitis B virus burden in developing countries. World J Gastroenterol 21 (2015), 11941–11953.
6. Maynard, JE, Hepatitis B: global importance and need for control. Vaccine 8:suppl (1990), S18–S20.
7. McMahon, BJ, The natural history of chronic hepatitis B virus infection. Hepatology 49:suppl 5 (2009), S45–S55.
8. Lin, X, Robinson, NJ, Thursz, M, et al. Chronic hepatitis B virus infection in the Asia-Pacific region and Africa: review of disease progression. J Gastroenterol Hepatol 20 (2005), 833–843.
9. Ladep, NG, Lesi, OA, Mark, P, et al. Problem of hepatocellular carcinoma in West Africa. World J Hepatol 6 (2014), 783–792.
10. Yang, JD, Mohamed, EA, Aziz, AO, et al. Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium. Lancet Gastroenterol Hepatol 2 (2017), 103–111.
11. Lemoine, M, Thursz, MR, Battlefield against hepatitis B infection and HCC in Africa. J Hepatol 66 (2017), 645–654.
12. Kew, MC, Epidemiology of hepatocellular carcinoma in sub-Saharan Africa. Ann Hepatol 12 (2013), 173–182.
13. Crocker-Buque, T, Pollock, AM, Appraising the quality of sub-Saharan African cancer registration systems that contributed to GLOBOCAN 2008: a review of the literature and critical appraisal. J R Soc Med 108 (2015), 57–67.
14. Kourtis, AP, Bulterys, M, Hu, DJ, Jamieson, DJ, HIV–HBV co-infection—a global challenge. N Engl J Med 366 (2012), 1749–1752.
15. Matthews, PC, Geretti, AM, Goulder, PJ, Klenerman, P, Epidemiology and impact of HIV coinfection with hepatitis B and hepatitis C viruses in sub-Saharan Africa. J Clin Virol 61 (2014), 20–33.
16. Sangaré, L, Sombié, R, Combasséré, AW, et al. Antenatal transmission of hepatitis B virus in an area of HIV moderate prevalence, Burkina Faso. Bull Soc Pathol Exot 102 (2009), 226–229 (in French).
17. Hoffmann, CJ, Thio, CL, Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis 7 (2007), 402–409.
18. Puoti, M, Torti, C, Bruno, R, Filice, G, Carosi, G, Natural history of chronic hepatitis B in co-infected patients. J Hepatol 44:suppl 1 (2006), S65–S70.
19. Hughes, SA, Wedemeyer, H, Harrison, PM, Hepatitis delta virus. Lancet 378 (2011), 73–85.
20. Apata, IW, Averhoff, F, Pitman, J, et al., on behalf of the Centers for Disease Control and Prevention (CDC). Progress toward prevention of transfusion-transmitted hepatitis B and hepatitis C infection—sub-Saharan Africa, 2000–2011. MMWR Morb Mortal Wkly Rep 63 (2014), 613–619.
21. WHO. Global status report on blood safety and availability 2016. 2017, World Health Organization, Geneva http://apps.who.int/iris/bitstream/10665/254987/1/9789241565431-eng.pdf (accessed Sept 29, 2017).
22. Stabinski, L, Reynolds, SJ, Ocama, P, et al. High prevalence of liver fibrosis associated with HIV infection: a study in rural Rakai, Uganda. Antivir Ther 16 (2011), 405–411.
23. Mphahlele, MJ, Impact of HIV co-infection on hepatitis B prevention and control: a view from sub-Saharan Africa. South Afr J Epidemiol Infect 23 (2008), 14–18.
24. Mayaphi, SH, Roussow, TM, Masemola, DP, Olorunju, SA, Mphahlele, MJ, Martin, DJ, HBV/HIV co-infection: the dynamics of HBV in South African patients with AIDS. S Afr Med J 102 (2012), 157–162.
25. Andersson, MI, Maponga, TG, Ijaz, S, et al. The epidemiology of hepatitis B virus infection in HIV-infected and HIV-uninfected pregnant women in the Western Cape, South Africa. Vaccine 31 (2013), 5579–5584.
26. Thio, CL, Seaberg, EC, Skolasky, R Jr, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 360 (2002), 1921–1926.
27. Puoti, M, Spinetti, A, Ghezzi, AJ, et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr 24 (2000), 211–217.
28. Weber, R, Sabin, CA, Friis-Møller, N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 166 (2006), 1632–1641.
29. Sonderup, MW, Wainwright, H, Hall, P, Hairwadzi, H, Spearman, CW, A clinicopathological cohort study of liver pathology in 301 patients with human immunodeficiency virus/acquired immune deficiency syndrome. Hepatology 61 (2015), 1721–1729.
30. Falade-Nwulia, O, Seaberg, EC, Rinaldo, CR, Badri, S, Witt, M, Thio, CL, Comparative risk of liver-related mortality from chronic hepatitis B versus chronic hepatitis C virus infection. Clin Infect Dis 55 (2012), 507–513.
31. El-Sadr, WM, Lundgren, JD, Neaton, JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 355 (2006), 2283–2296.
32. Wandeler, G, Gsponer, T, Bihl, F, et al. Hepatitis B virus infection is associated with impaired immunological recovery during antiretroviral therapy in the Swiss HIV Cohort Study. J Infect Dis 208 (2013), 1454–1458.
33. Dore, GJ, Soriano, V, Rockstroh, J, et al. Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption. AIDS 24 (2010), 857–865.
34. Chun, HM, Roediger, MP, Hullsiek, KH, et al. Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters. J Infect Dis 205 (2012), 185–193.
35. Keane, E, Funk, AL, Shimakawa, Y, Systematic review with meta-analysis: the risk of mother-to-child transmission of hepatitis B virus infection in sub-Saharan Africa. Aliment Pharmacol Ther 44 (2016), 1005–1017.
36. Brown, RS Jr, McMahon, BJ, Lok, AS, et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: a systematic review and meta-analysis. Hepatology 63 (2016), 319–333.
37. Han, L, Zhang, HW, Xie, JX, Zhang, Q, Wang, HY, Cao, GW, A meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus. World J Gastroenterol 17 (2011), 4321–4333.
38. Zou, H, Chen, Y, Duan, Z, Zhang, H, Pan, C, Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers. J Viral Hepat 19 (2012), e18–e25.
39. Lee, C, Gong, Y, Brok, J, Boxall, EH, Gluud, C, Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ 332 (2006), 328–336.
40. WHO. Expanded programme on immunization. Global Advisory Group—Part 1. Wkly Epidemiol Rec 67 (1992), 11–15.
41. Ott, JJ, Stevens, GA, Groeger, J, Wiersma, ST, Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 30 (2012), 2212–2219.
42. WHO. Hepatitis B vaccines: WHO position paper. Weekly Epidemiological Record 84 (2009), 405–420.
43. WHO. WHO-UNICEF estimates of HepB-BD coverage. http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tswucoveragehepb_bd.html, 2017 (accessed July 24, 2017).
44. Breakwell, L, Tevi-Benissan, C, Childs, L, Mihigo, R, Tohme, R, The status of hepatitis B control in the African region. Pan Afr Med J, 27(suppl 3), 2017, 17.
45. WHO. SAGE meeting of October 2016. A systematic review of monovalent hepatitis B vaccine thermostability. http://www.who.int/immunization/sage/meetings/2016/october/6_Thermostability_HBV_04102016.pdf, October, 2016 (accessed Oct 2, 2017).
46. Hipgrave, DB, Maynard, JE, Biggs, BA, Improving birth dose coverage of hepatitis B vaccine. Bull World Health Organ 84 (2006), 65–71.
47. WHO. Preventing perinatal hepatitis B virus transmission: a guide for introducing and strengthening hepatitis B birth dose vaccination. December, 2015, World Health Organization, Geneva https://www.who.int/iris/handle/10665/208278 (accessed Feb 1, 2017).
48. Tharmaphornpilas, P, Rasdjarmrearnsook, AO, Plianpanich, S, Sa-nguanmoo, P, Poovorawan, Y, Increased risk of developing chronic HBV infection in infants born to chronically HBV infected mothers as a result of delayed second dose of hepatitis B vaccination. Vaccine 27 (2009), 6110–6115.
49. Chien, YC, Jan, CF, Chiang, CJ, Kuo, HS, You, SL, Chen, CJ, Incomplete hepatitis B immunization, maternal carrier status, and increased risk of liver diseases: a 20-year cohort study of 3·8 million vaccinees. Hepatology 60 (2014), 125–132.
50. Cui, F, Liang, X, Gong, X, et al. Preventing hepatitis B though universal vaccination: reduction of inequalities through the GAVI China project. Vaccine 31:suppl 9 (2013), J29–J35.
51. Zhang, H, Pan, CQ, Pang, Q, Tian, R, Yan, M, Liu, X, Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. Hepatology 60 (2014), 468–476.
52. del Canho, R, Grosheide, PM, Schalm, SW, de Vries, RR, Heijtink, RA, Failure of neonatal hepatitis B vaccination: the role of HBV-DNA levels in hepatitis B carrier mothers and HLA antigens in neonates. J Hepatol 20 (1994), 483–486.
53. Xu, WM, Cui, YT, Wang, L, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a muticentre, randomized, double-blind, placebo-controlled study. J Viral Hepat 16 (2009), 94–103.
54. Han, GR, Cao, MK, Zhao, W, et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol 55 (2011), 1215–1221.
55. Pan, CQ, Duan, Z, Dai, E, et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med 374 (2016), 2324–2334.
56. Terrault, NA, Bzowej, NH, Chang, KM, Hwang, JP, Jonas, MM, Murad, MH, AASLD guidelines for treatment of chronic hepatitis B. Hepatology 63 (2016), 261–283.
57. European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol 67 (2017), 370–398.
58. WHO. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. March, 2015, World Health Organization, Geneva www.who.int/hiv/pub/hepatitis/hepatitis-b-guidelines/en/ (accessed Jan 8, 2017).
59. Wen, WH, Huang, CW, Chie, WC, et al. Quantitative maternal hepatitis B surface antigen predicts maternally transmitted hepatitis B virus infection. Hepatology 64 (2016), 1451–1461.
60. Hsu, HM, Chen, DS, Chuang, CH, et al. Efficacy of a mass hepatitis B vaccination program in Taiwan. Studies on 3464 infants of hepatitis B surface antigen-carrier mothers. JAMA 260 (1988), 2231–2235.
61. Chen, HL, Chang, MH, Ni, YH, et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA 276 (1996), 906–908.
62. Ni, YH, Chang, MH, Huang, LM, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med 135 (2001), 796–800.
63. Chang, MH, You, SL, Chen, CJ, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 101 (2009), 1348–1355.
64. Wichajarn, K, Kosalaraksa, P, Wiangnon, S, Incidence of hepatocellular carcinoma in children in Khon Kaen before and after national hepatitis B vaccine program. Asian Pac J Cancer Prev 9 (2008), 507–509.
65. McMahon, BJ, Bulkow, LR, Singleton, RJ, et al. Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program. Hepatology 54 (2011), 801–807.
66. Kim, H, Shin, AR, Chung, HH, et al. Recent trends in hepatitis B virus infection in the general Korean population. Korean J Intern Med 28 (2013), 413–419.
67. Qu, C, Chen, T, Fan, C, et al. Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow-up of the Qidong hepatitis B intervention study: a cluster randomized controlled trial. PLoS Med, 11, 2014, e1001774.
68. Burnett, RJ, Kramvis, A, Dochez, C, Meheus, A, An update after 16 years of hepatitis B vaccination in South Africa. Vaccine 30:suppl 3 (2012), C45–C51.
69. Burnett, RJ, Ngobeni, JM, François, G, et al. Increased exposure to hepatitis B virus infection in HIV-positive South African antenatal women. Int J STD AIDS 18 (2007), 152–156.
70. Firnhaber, C, Reyneke, A, Schulze, D, et al. The prevalence of hepatitis B co-infection in a South African urban government HIV clinic. S Afr Med J 98 (2008), 541–544.
71. Lukhwareni, A, Burnett, RJ, Selabe, SG, Mzileni, MO, Mphahlele, MJ, Increased detection of HBV DNA in HBsAg-positive and HBsAg-negative South African HIV/AIDS patients enrolling for highly active antiretroviral therapy at a tertiary hospital. J Med Virol 81 (2009), 406–412.
72. Boyles, TH, Cohen, K, The prevalence of hepatitis B infection in a rural South African HIV clinic. S Afr Med J 101 (2011), 470–471.
73. Andersson, MI, Maponga, TG, Ijaz, S, et al. The epidemiology of hepatitis B virus infection in HIV-infected and HIV-uninfected pregnant women in the Western Cape, South Africa. Vaccine 31 (2013), 5579–5584.
74. Njai, HF, Shimakawa, Y, Sanneh, B, et al. Validation of rapid point-of-care (POC) tests for detection of hepatitis B surface antigen in field and laboratory settings in The Gambia, Western Africa. J Clin Microbiol 53 (2015), 1156–1163.
75. Lemoine, M, Shimakawa, Y, Njie, R, et al. Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) study. Lancet Glob Health 4 (2016), e559–e567.
76. Nayagam, S, Conteh, L, Sicuri, E, et al. Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis. Lancet Glob Health 4 (2016), e568–e578.
77. Chang, TT, Liaw, YF, Wu, SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 52 (2010), 886–893.
78. Marcellin, P, Gane, E, Buti, M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 381 (2013), 468–475.
79. Wong, GL, Chan, HL, Mak, CW, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 58 (2013), 1537–1547.
80. Chan, HLY, Fung, S, Seto, WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol 1 (2016), 185–195.
81. Buti, M, Gane, E, Seto, WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol 1 (2016), 196–206.
82. Murakami, H, Van Cuong, N, Huynh, L, Hipgrave, DB, Implementation of and costs associated with providing a birth-dose of hepatitis B vaccine in Viet Nam. Vaccine 26 (2008), 1411–1419.
83. Creati, M, Saleh, A, Ruff, TA, et al. Implementing the birth dose of hepatitis B vaccine in rural Indonesia. Vaccine 25 (2007), 5985–5993.
84. Ghosh, S, Sow, A, Guillot, C, et al. Implementation of an in-house quantitative real-time polymerase chain reaction method for hepatitis B virus quantification in West African countries. J Viral Hepat 23 (2016), 897–904.
85. Arora, S, Kalishman, S, Thornton, K, et al. Expanding access to hepatitis C virus treatment—Extension for Community Healthcare Outcomes (ECHO) project: disruptive innovation in specialty care. Hepatology 52 (2010), 1124–1133.
86. WHO. Global health sector strategy on viral hepatitis 2016–2021. June, 2016, World Health Organization, Geneva www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/ (accessed Oct 4, 2017).